Showing 1 to 8 of 8 Clinical Trials
|
CLINICAL TRIAL Trial No ClinicalTrials.gov ID |
Principal Investigator
Coordinator |
||
|---|---|---|---|
|
A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers
MK-9999-02A NCT06428409  Recruiting
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Colon and Rectum Hepatic Ducts Pancreas |
Dr. Francine Aubin Adeline Hamon 514-890-8000 poste 30737 |
|
A Phase 2 Nonrandomized, Open-label, Multisite Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan in Participants With Gastrointestinal Cancers
MK-5909-005 (REJOICE-GI01) NCT06864169 Recruiting
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Colon and Rectum Hepatic Ducts Oesophagus Pancreas Stomach |
Dr. Francine Aubin Adeline Hamon 514-890-8000 poste 30737 |
|
A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers
MK-9999-02A NCT06428409 Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Colon and Rectum Hepatic Ducts Pancreas |
Dr. Victoria Mandilaras Rodrigo Skowronski 514-934-1934 poste 36275 |
|
A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig Versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer
DESTINY-Biliary Tract Cancer-01 NCT06467357 Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Hepatic Ducts |
Dr. Victoria Mandilaras Amanda McFarlan 514-934-1934 poste 44205 |
|
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent
ARTEMIDE-Biliary01 NCT06109779 Recruiting
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS
|
Hepatic Ducts |
Dr. Maxime Chénard-Poirier Alice Ndayizigiye 418-525-4444 poste 15782 |
|
Comprehensive Molecular Profiling of Advanced Biliary Tract Cancers for Better Treatment Selection: a McGill University Health Centre Study
COMPASS-B-MUHC NCT04318834 Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Hepatic Ducts |
Dr. George Zogopoulos Crystal Haigh 514-934-1934 poste 76333 |
|
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent
ARTEMIDE-Biliary01 NCT06109779 Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Hepatic Ducts |
Dr. Jamil Asselah Amanda McFarlan 514-934-1934 poste 44205 |
|
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 in Combination With Other Therapies in Subjects With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous MTAP-deletion
20230223 NCT06360354 Recruiting
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS
|
Hepatic Ducts Pancreas |
Dr. Maxime Chénard-Poirier Maryse Gingras 418-525-4444 poste 15781 |
Groupe d'étude en oncologie du Québec